|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Increasing evidence indicates that BAF53a is crucial for embryonic development and maintenance of stemness, and may be associated with epithelial-mesenchymal transition (EMT), which suggests its involvement in cancer progression.
|
29039584 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that ACTL6A may contribute to cancer progression by stabilizing YAP/TAZ and therefore provide a novel therapeutic target for the treatment of human gliomas.
|
29725063 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Actin-like 6A (ACTL6A) is vital for embryogenesis and differentiation and is also critical for metastasis and EMT in hepatocellular carcinoma, as observed in our previous study.
|
30348114 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
|
28041841 |
2017 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Childhood Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Acquired aplastic anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, gene expression analysis identified a significant loss of the SWI/SNF core component SMARCC1, along with ARID1B, ACTL6A, and SMARCD1, in human AA BM CD34<sup>+</sup> HSCs and hematopoietic stem and progenitor cells (HSPCs) compared with normal HSPCs.
|
29596882 |
2018 |
|
Adult Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Whether SOX2 and ACTL6A/TP63 interact with the Hippo-YAP1 pathway in esophageal squamous cell carcinoma (ESCC) remains unclear.
|
31560173 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, ACTL6A and p63 collaborate as oncogenic drivers in HNSCC.
|
28041841 |
2017 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Both in vitro and in vivo assays showed that ACTL6A overexpression promoted osteosarcoma cell invasion and metastasis, whereas knockdown of ACTL6A expression reduced osteosarcoma cell malignant behavior such as invasion and metastasis.
|
28260090 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
ACTL6A overexpression promoted migration and invasion of colon cancer cells, whereas ACTL6A knockdown exhibited the opposite effect in vitro.
|
30348114 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The data from both the Gene Expression Omnibus (GEO) and Oncomine databases showed that ACTL6A expression levels in colon adenoma and cancer were higher than those in normal colon samples.
|
30348114 |
2018 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analyses of osteosarcoma tissue samples from two independent cohorts of formaldehyde-fixed, paraffin-embedded osteosarcoma tissue samples from total of 186 osteosarcoma patients showed that high ACTL6A expression correlated with malignant clinicopathological features such as larger tumor size, high Ennecking grade, high histologic grade, and advanced tumor node metastasis stage.
|
28260090 |
2017 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Increased Actin-like 6A (ACTL6A) expression has been implicated in the development of diverse cancers and recently associated with the Hippo signaling pathway, which is known to regulate biological properties, including proliferation, tissue regeneration, stem cell biology, as well as tumorigenesis.
|
29725063 |
2018 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Ectopic ACTL6A/p63 expression promotes tumorigenesis, while ACTL6A expression and YAP activation are highly correlated in primary HNSCC and predict poor patient survival.
|
28041841 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The data from both the Gene Expression Omnibus (GEO) and Oncomine databases showed that ACTL6A expression levels in colon adenoma and cancer were higher than those in normal colon samples.
|
30348114 |
2018 |